Thank you, Keith.
of we all mentioned, I our across As make continue programs. progress excellent development four to clinical
First, I OAB programs about of will talk vibegron. the
EMPOWUR progress continue Phase following malignant the the positive great bladder. filing, study the overactive results We NDA vibegron for from on make to vibegron III topline of
ambulatory that report now blood primary study. achieved to we've the pleased are We the pressure endpoints for
the less the XX% day I vibegron placebo. baseline for than confidence an relative rule daytime X.X limit be to ruled FDA reviewed to protocol daytime of Mercury pressure the upper to The endpoint this predefined primary an placebo out mean of was ambulatory The systolic XX The pressure. vibegron blood from protocol ambulatory to systolic the to effect variable change out the to blood for be pressure mean in was daytime purpose The study the blood ambulatory blood of was that systolic XXXX. mm effective in of compared fall by vibegron, in interval for systolic had pressure.
enrolled XX versus as FDA years study In Men XXX U.S. sites. XX has similar to women target a study study the population drug with and one-to-one accordance of controlled the subjects was This The aged and XX across characteristics OAB. with randomization. population. XX guidance, mg a placebo
of study the dose and four. XX-hour was based at plan measured four with weeks FDA. The was vibegron the XX for mg ambulatory blood study two at on The pressure registration the and was baseline weeks duration
rate mean the diastolic maximum a baseline with dosing. half heart endpoints full to diastolic as and changes daytime hours pressure change and XX change in rates as and blood minutes the a XX systolic post and pressure Secondary six and well in from heart mood hour
years. A XX% study. the XXX XX subjects group. of completed the treatment into total subjects of enrolled were XXX XX of was the the placebo age were into vibegron group, the female and mean subjects the subjects
mm the upper relevant X.X a X.XX has ambulatory study The interval the of pressure the in are minus confidence treatment as blood X.XX primary plus FDA. of results ambulatory Therefore, X.X clinically mean mercury with pressure mm with interval mercury for successful today placebo never X.XX. vibegron systolic study the bound blood to group in XX% change daytime vibegron vibegron. mercury, the pressure was each XX the as agreed blood confidence this follows; of for a out achieved mm predefined was baseline square increase ruled The of endpoint minus study of The crossed from
data is ambulatory The confidence different statistically from indicates interval placebo. from that zero, pressure includes which change not the mean blood baseline
take systolic minute. and for XX mm placebo plus X.XX to treatment full difference were baseline the blood ambulatory X.XX diastolic mm trace the provider pressure, plus day beats minus from pressure heart Mercury a for per X.XX of is the XX-hour blood For Mercury
vibegron There the was in placebo statistically or endpoints. compared these difference any significant no endpoints to of of primary
percentage clinic clinically visit, signs, vital of XX millimeter having were or blood to was changes small increase mercury patients compared pressure millimeter not pressure a XX the in Regarding increases the from blood in placebo. systolic categorical in baseline, they systolic relevant
study Phase the and interest upper tract consistent III X%. The being the adverse urinary infection, common event below diarrhea, with profile tract infections, headaches, respiratory average was EMPOWUR most with events
adverse there in to the medication vibegron hypertension, of in loss one increase Of to placebo note blood event more five subject pressure. placebo. was is compared the Therefore the a group. performance the the group taking and the known event that was group Regarding which in weight one vibegron group vibegron
these We with vibegron. and leading they experts study very outcome that favorable these cardiology for have agreed a results represent discussed results
and the we III manuscript globally study to in the Phase September. further EMPOWUR of and are study the sum, Phase favorable will results confirms present for To results study study III the the preparing In look results publication forward the further we in overall this Gothenburg, at the International profile Continence the on discussing EMPOWUR of Society FDA. safety Sweden with momentum, observed the EMPOWUR meeting build
In with the meantime, expected the this EMPOWUR the end data by long III continues term of progress of portion well, Phase quarter. the study to extension
on We meeting are a but continuing productive preparations NDA this in XXXX. with we FDA. our early the earlier the new drug pre-NDA year to submit track We're indication by with application had the
continuing filing of fourth is to into note, quarter year. the this team the make effort accelerate Of to every the
BPH, of the X XX an the completed recommendation is safety initial hyperplasia our safety development we quarter. and with enrollment data have from supplemental assessment patients Part OAB expected programs in h assessment in men the monitoring Regarding vibegron in in or board of benign prostatic fourth
as men important start bladder two milestone there patients in efficacy trial there's currently specifically to products BPH. overactive approved with will assess of is and indicated Part the an safety no FDA and for
at primary and pain the IBS devoid, associated enroll and for Key endpoints pain awakening for episodes, of which IBS to abdominal goes safety. patients XX reduction at to weekly night is mixed be averages. defined a core an with in prostate endpoint for zero decrease urgency from A will randomized responder are XX due to endpoints a is diarrhea with duration The with IBS in secondary primary reduction with with subject reduction XXX on IBS-D. The a XX intensity which the to nocturia point XX to XX% The or worst baseline week scores or compared pain placebo. frequency at XX symptom least plan milligram episodes as IBS continues is vibegron clinical abdominal associated to abdominal enroll scale females rating XX% the with program hours. in pain either
and stool Secondary on in endpoints include particular consistency. global safety lack rating the effects scale frequency negative of or the
expect topline data We in report XXXX. to
pleased for and end at OAB therapy in start XXXX. gene are Xa of we Phase announce preparing URO-XXX, been ejectable finalized protocol that the novel quarter enrollment patient has to the to our fourth we're the regarding Finally,
to Christine Now update. financial I’ll onto pass
